All In Biotech

Drug Trial Radar · NCT04777006

Integrating a Stepped Care Model of Screening and Treatment for Depression Into Malawi's National HIV Care Delivery Platform

Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 487 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

487

Actual

Start

Sep 1, 2021

Primary completion

Apr 30, 2023

Study completion Jun 30, 2025

Sponsor

Lead sponsor
RANDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Mental Health (NIMH); Partners in Health; Brigham and Women's Hospital; Ministry of Health, Malawi; Blantyre College of Medicine; University of Birmingham
First posted
Mar 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Double (care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Malawi is a low-income country in sub-Saharan Africa that has limited resources to address a significant burden of disease-including HIV/AIDS. Additionally, depression is a leading cause of disability in the country but largely remains undiagnosed and untreated. Lack of cost-effective, scalable solutions is a fundamental barrier to expanding depression treatment. Against this backdrop, one major success has been the scale-up of a network of more than 700 HIV clinics, with over half a million patients enrolled in ART. As a chronic care system with dedicated human resources and infrastructure, this presents a strategic platform for integrating depression care, and responds to a robust evidence base outlining the bi-directionality of depression and HIV outcomes. The investigators will evaluate a stepped model of depression care that combines group-based Problem Management Plus (group PM+) with antidepressant therapy (ADT) for 420 adults with moderate/severe depression in Neno District, Malawi, as measured by the Patient Health Questionnaire-9 (PHQ-9). Rollout will follow a stepped-wedge cluster randomized design in which 14 health facilities are randomized to implement the model in five steps over a 15-month period. Primary outcomes (depression symptoms, functional impairment, and overall health) and secondary outcomes (e.g. HIV: viral load, ART adherence; diabetes: A1C levels, treatment adherence; hypertension: systolic blood pressure, treatment adherence) will be measured every three months through 12-month follow-up. The investigators will also evaluate the model's cost-effectiveness, quantified as an incremental cost-effectiveness ratio (ICER) compared to baseline chronic care services in the absence of the intervention model. This study will conduct a stepped-wedge cluster randomized trial to compare the effects of an evidence-based depression care model versus usual care on depression symptom remediation as well as physical health outcomes for chronic care conditions. The investigators will also look at the indirect effects of the intervention at the household level. The investigators' hypothesis is that the intervention will be effective at reducing depression symptoms, improving physical health, and improving household members' wellbeing, compare to treatment as usual. The investigators also hypothesize that the intervention will be highly cost-effective, meaning that the cost per QALY gained will be less than Malawi's median GDP per capita. If determined to be effective and cost-effective, this study will provide a model for integrating depression care into HIV clinics in additional districts of Malawi and other low-resource settings with high HIV prevalence.

Conditions

  • Depressive Disorder

Interventions

  • Problem Management PlusBehavioral

    PM+ is a cognitive-behavioral intervention that trains recipients to improve their management of practical problems, and uses the term "problem management" rather than "problem solving" to emphasize that many problems encountered by individuals living in adverse circumstances may not be "solvable". The "plus" in PM+ underscores additional evidence-based behavioral strategies incorporated into the model, including: stress management strategies, behavioral activation, and social support strengthening. In total, PM+ comprises five sessions held once per week for 1.5. to 2.5 hours per session. The model has shown success in reducing depression symptoms in low-resource settings such as Nepal and Pakistan.4

  • Antidepressant TherapyDrug

    Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary. Neno District supply chain is supported by PIH, which reduces stock-outs relative to those observed in other Malawian settings. Fluoxetine is typically the first drug of choice because it is safer and better tolerated. Daily dose will commence at 20 mg of fluoxetine, or 25 mg of amitriptyline. At monthly follow-up visits, a dose increment or medication change may be considered based on measures of treatment response and side effects, using an Antidepressant Side Effect Checklist. This algorithm-based process will be repeated every other week until the patient is fully responding to treatment (PHQ-9 \< 5) for a period of three months. Dose escalations of more than one increment and medication changes will be reviewed with the doctor-in-charge. If on ADT at end of study, it will be sustained as part of usual care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Depression Symptoms (PHQ-9), 3 Months Post-intervention for All Participants (i.e., for Each Arm)Time frame: 3 months post-intervention for all participants (i.e., for each arm)
  2. Depression Symptoms (PHQ-9), 6 Months Post-intervention for All Participants (i.e., for Each Arm)Time frame: 6 months post-intervention for all participants (i.e., for each arm)
  3. Depression Symptoms (PHQ-9), 9 Months Post-intervention for All Participants (i.e., for Each Arm)Time frame: 9 months post-intervention for all participants (i.e., for each arm)
  4. Depression Symptoms (PHQ-9), 12 Months Post-intervention for All Participants (i.e., for Each Arm).Time frame: 12 months post-intervention for all participants (i.e., for each arm).
  5. Functional Impairment (WHO Disability Assessment Schedule), 3 Months Post-intervention for All Participants (i.e., for Each Arm).Time frame: 3 months post-intervention for all participants (i.e., for each arm).
  6. Functional Impairment (WHO Disability Assessment Schedule), 6 Months Post-intervention for All Participants (i.e., for Each Arm).Time frame: 6 months post-intervention for all participants (i.e., for each arm).
  7. Functional Impairment (WHO Disability Assessment Schedule), 9 Months Post-intervention for All Participants (i.e., for Each Arm).Time frame: 9 months post-intervention for all participants (i.e., for each arm).
  8. Functional Impairment (WHO Disability Assessment Schedule), 12 Months Post-intervention for All Participants (i.e., for Each Arm).Time frame: 12 months post-intervention for all participants (i.e., for each arm).
  9. Overall Health Profile (EQ-5D-5L), 3 Months Post-intervention for All Participants (i.e., for Each Arm).Time frame: 3 months post-intervention for all participants (i.e., for each arm).
  10. Overall Health Profile (EQ-5D-5L), 6 Months Post-intervention for All Participants (i.e., for Each Arm).Time frame: 6 months post-intervention for all participants (i.e., for each arm).
  11. Overall Health Profile, 9 Months Post-intervention for All Participants (i.e., for Each Arm).Time frame: 9 months post-intervention for all participants (i.e., for each arm).
  12. Overall Health Profile, 12 Months Post-intervention for All Participants (i.e., for Each Arm).Time frame: 12 months post-intervention for all participants (i.e., for each arm).
  13. Prevalence of Depression (PHQ-9 Score > 9), 3-months Post-intervention for All Participants (for Each Arm).Time frame: 3 months post-intervention for all participants (for each arm).
  14. Prevalence of Depression (PHQ-9 Score > 9), 6-months Post-intervention for All Participants (for Each Arm).Time frame: 6 months post-intervention for all participants (for each arm).
  15. Prevalence of Depression (PHQ-9 Score > 9), 9-months Post-intervention for All Participants (for Each Arm).Time frame: 9 months post-intervention for all participants (for each arm).
  16. Prevalence of Depression (PHQ-9 Score > 9), 12-months Post-intervention for All Participants (for Each Arm).Time frame: 12 months post-intervention for all participants (for each arm).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Partners In Health

    Neno, Neno District, Malawi

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.